Company Filing History:
Years Active: 2015-2017
Title: Benoît Destenaves: Innovator in Growth Hormone Therapy
Introduction
Benoît Destenaves is a notable inventor based in Peron, France. He has made significant contributions to the field of genetic research, particularly in the context of growth hormone therapy. His work focuses on improving treatment outcomes for patients with Growth Hormone Deficiency (GHD) and Turner Syndrome (TS).
Latest Patents
Benoît Destenaves holds a patent for "Genomic markers for prediction of long-term response to growth hormone (GH) therapy." This invention relates to the use of genetic markers to identify the response to growth hormone treatment in patients suffering from GHD or TS. It also includes methods for treating these patients and kits for genotyping.
Career Highlights
Benoît Destenaves is associated with Merck Serono S.A., a leading biopharmaceutical company. His work at Merck Serono has allowed him to contribute to advancements in medical treatments and genetic research.
Collaborations
He has collaborated with notable colleagues such as Pascal Croteau and John Raelson, enhancing the impact of his research through teamwork and shared expertise.
Conclusion
Benoît Destenaves is a pioneering inventor whose work in genomic markers has the potential to transform growth hormone therapy for patients with specific medical conditions. His contributions to the field are invaluable and continue to influence future research and treatment methodologies.